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Abstract 
We report the case of a 50-year-old woman with a history of diabetes mellitus who 
underwent left breast lumpectomy and ipsilateral lymphadenectomy in 1994 because of an 
infiltrating ductal carcinoma. Chemotherapy followed by radiotherapy to the breast and 
nodal areas were performed. In 2010, in a routine screening for diabetic retinopathy, two 
choroidal elevated masses above and below the optic nerve associated to serous retinal 
detachment of her right eye were noted. The patient was asymptomatic. Carcinoma was 
positive for hormone receptor. Hormone treatment with letrozole was established. 
Complete regression of the choroidal metastasis was observed 3 months later. 
Ophthalmologic screening in asymptomatic patients with breast cancer has the advantage of 
being a noninvasive procedure and enables an early treatment in isolated cases. However, 
some studies are an argument against the usefulness of eye screening due to the low 
incidence of asymptomatic choroidal metastasis and the cost that involves performing it 
routinely in a large number of patients. Aromatase inhibitors are well-tolerated drugs that 
may be a powerful tool in the management of metastatic breast cancer that express 
hormone receptors. 
 
Introduction 
Uveal metastasis is the most frequent intraocular tumor and the choroid is the most 
commonly involved site [1]. Although breast carcinomas usually metastasize to the eye, 
the incidence of asymptomatic choroidal metastasis from disseminated breast cancer is 
low [1, 2]. Eye screening in these patients remains controversial.  
Case Rep Ophthalmol 2011;2:382–386 
DOI: 10.1159/000334937 
Published online: 
December 10, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
 
 
 
383 
Methods 
A 50-year-old woman with a history of diabetes mellitus underwent left breast lumpectomy and 
ipsilateral lymphadenectomy in 1994 because of an infiltrating ductal carcinoma of 15 mm in 
diameter, which was classified as grade 2. The estrogen and progesterone receptors were positive. 
The infiltrating ductal carcinoma was classified as a pT1N1M0, stage IIA. Cyclophosphamide, 
methotrexate and 5-fluorouracil for 6 cycles followed by radiotherapy to the breast and nodal areas 
were performed. She continued treatment with tamoxifen for 5 years. 
In 2000, the patient presented with an endometrial adenocarcinoma stage IIIA. Hysterectomy and 
bilateral oophorectomy were then performed. She received adjuvant chemotherapy with 
cyclophosphamide, doxorubicin and cisplatin scheme for a total of 3 cycles followed by pelvic 
radiotherapy and brachytherapy overdose.  
In February 2010, in a routine screening for diabetic retinopathy, two choroidal elevated masses 
above and below the optic nerve associated to serous retinal detachment of her right eye were noted 
(fig. 1). The left eye was normal. The patient was asymptomatic, with a best corrected visual acuity of 
20/20 in both eyes. The ultrasound exam showed 2 masses located in the choroid with middle 
reflectivity and irregular internal structure without kappa angle or choroidal excavation. Fluorescein 
angiography showed a mottled hyperfluorescence in the areas of the lesions with fluorescein slight 
increase over time. Bone scintigraphy, thoracic computed tomography and abdominal echography 
were performed. A positive biopsy of the left axillary lymph node confirmed systemic recurrence after 
16 years from diagnosis. Carcinoma was positive for hormone receptor but negative for Her2-Neu. 
Results 
Hormone treatment with letrozole and zoledronic acid was established. Complete 
regression of the choroidal (fig. 2) and lymph metastasis was observed 3 months later. 
At present, our patient shows a complete remission of her disease. 
Discussion 
The incidence of ocular metastasis from breast cancer ranges from 3 to 30% [3, 4]. It 
usually occurs 3–5 years after the diagnosis. Our patient developed recurrence 16 years 
from diagnosis, being asymptomatic at onset. In a review of 264 patients with choroidal 
metastasis from breast cancer, Shields and coworkers [1] found only a total of 7% of 
asymptomatic patients. In these patients attempts to demonstrate the usefulness of 
screening for choroidal metastasis have been done. Three studies conducted in patients 
with advanced disease have shown the potential role of the screening. The frequency of 
asymptomatic choroidal metastasis was 0, 0, and 5%, respectively [4–6], increasing up 
to 11% in patients with more than one site of metastasis in the last study. 
The frequency of choroidal metastasis has decreased in recent years. This can be 
explained by the improvement of the adjuvant therapy in the management of breast 
cancer (both chemotherapy and hormonal therapy) [7]. It is particularly effective in the 
eradication of metastasis of less than 1 mm in diameter in well-vascularized tissues 
such as the choroid. 
Ophthalmologic screening in asymptomatic patients with breast cancer has the 
advantage of being a noninvasive procedure and enables an early treatment in isolated 
cases. However, the previously cited studies are an argument against the usefulness of  
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eye screening due to the low incidence of asymptomatic choroidal metastasis and the 
cost that involves performing it routinely in a large number of patients. 
Treatment of choroidal metastasis depends on several factors including the location, 
number and spread of primary tumor. Therapeutic options include systemic treatment 
(chemotherapy and hormone therapy), external beam radiotherapy (EBRT), local 
resection, photocoagulation, transpupillary thermotherapy, cryotherapy and 
enucleation. 
Estrogen is an important hormone involved in the development and growth of 
breast tumors. Hormone therapy is used for those tumors that express hormone 
receptors. It has been found that 60–70% of breast cancers have estrogen receptors. In 
postmenopausal women, the main source of estrogen comes from peripheral 
conversion of adrenal androgen. The aromatase inhibitors are a group of drugs that act 
by preventing this conversion, decreasing circulating estrogen levels. New third 
generation aromatase inhibitors include anastrozole, letrozole and exemestane [8]. 
In a case series reported by Manquez et al. [9], 17 cases of uveal metastasis were 
treated with one of these hormonal therapeutic agents. Both systemic and choroidal 
metastasis regressed in 10 cases (59% of cases) after a 20-months follow-up. 
In conclusion, aromatase inhibitors are well-tolerated drugs that may be a powerful 
tool in the management of metastatic breast cancer that express hormone receptors. 
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Fig. 1. Fundus photograph of the right eye showing a choroidal elevated mass below the optic nerve 
associated to serous retinal detachment. 
 
 
 
Fig. 2. Complete regression of the lesion was noted 3 months later. 
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